Pharmafile Logo

Wilmington Healthcare

A heritage to envy

Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS and Wellards to create an unrivalled healthcare data, education and information resource with outstanding analytics capabilities. Binley’s is a healthcare data and intelligence provider, which translates the complex NHS environment into useful information that helps organisations to increase sales, save money and improve healthcare. NHiS was founded in 2007 in response to a growing need in the marketplace for quantitative and qualitative data to inform service redesign and pathway efficiencies. Wellards provides the most up-to-date and comprehensive NHS information and training on the market.

What do we do?

Our close connections across the healthcare community, coupled with our high-quality data assets result in effective and actionable insights for our clients. We offer unrivalled expertise in:

  • In depth local UK healthcare knowledge
  • Close relationships with, and proximity to, the NHS
  • The largest collection of data assets in the UK
  • Customised intelligence
  • Service redesign
  • Industry standard-setting unique learning platform

How do we work?

We understand our customers’ requirements, no matter how complex they may be. Our team is skilled at tailoring the right solutions and supporting this journey every step of the way: from supplying data and insight, to engagement opportunities with stakeholders and health sector thought leaders. We will work closely with you to ensure you have the solution that meets your needs.

What results do we get?

Wilmington Healthcare aims to be your data and insight partner. We will provide you with the intelligence you need to transform outcomes for patients and your organisation. Through working with Wilmington Healthcare, our clients develop expertise in their area of focus, helping them to not only gain traction in the market but to achieve market-leading positions and the results to match.

Beechwood House, 2-3 Commercial Way, Christy Close, Southfields, Basildon, SS15 6EF, United Kingdom

- PMLiVE

  • Health data, analytics and insight
  • Education
  • Engagement and collaboration
  • Data, market insight and marketing services
  • NHS service transformation

UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW

Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...

MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE

With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...

ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS

With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...

HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW

Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...

ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE

With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.

Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...

EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES

As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...

UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS

Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...

Wilmington Healthcare appoints new director to lead cloud-based healthcare customer intelligence tool

Paul Rowe to lead intelligence tool that allows Industry to gain the complete picture of their changing NHS customer base and employ precision planning to access target customers and markets.

LOOKING AHEAD: UNDERSTANDING THE NHS CUSTOMER’S PRIORITIES FOR 2022/23

The recently published operational planning guidance describes what the NHS needs to achieve this year. Wilmington Healthcare’s Oli Hudson explores some of its critical themes and what they mean for...

Shining a light on the true cost of patient care

Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore how the proposed national patient data sharing scheme would change the NHS

How can pharma engage with the top performing STPs?

The recent announcement by Health Secretary Jeremy Hunt on which Sustainability and Transformation Partnerships (STPs) would benefit from a share of the £325m capital funding allocated in the Spring Budget,...

What will the NHS’s Capped Expenditure Process (CEP) mean for pharma?

Paul Midgley, Director of NHS Insight at Wilmington Healthcare, explains how pharma should tailor its approach

How will the NHS’s new medicines savings drive affect pharma?

Steve How and Sue Thomas, of Wilmington Healthcare, explore how pharma should engage with CCGs on prescribing saving targets

How can pharma help the NHS capitalise on its data?

Sue Thomas, Paul Midgley and Steve How, of Wilmington Healthcare, explain how pharma can work with the NHS to transform services

How can pharma engage with Accountable Care Systems?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, explain how pharma can add value across care pathways

How will capitated budgets affect NHS spending?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the implications of a single budget covering all the physical, mental and social care needs of patients in an STP

How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma

How will Sustainability and Transformation Plans (STPs) change the NHS in 2017?

Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the impact that STPs will have on the NHS and what this means for pharma.

How can pharma help the NHS drive much-needed change in mental health services?

Laurence Mascarenhas, of Wilmington Healthcare, assesses how pharma can help the NHS to achieve Parity of Esteem (PoE) in mental health

Considering a portfolio review?

Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...

Millennial Physicians And Digital Health Services

Can Millennial Physicians and Digital Health Services Fix the Patient-Doctor Relationship?

“High accuracy data, straight-forward customer service and instructions, and a smooth overall experience.”
Christos Begkos, University of Manchester

“Service redesign provided us with development of integrated, person-centred care and greater focus on proactive management of the neurology patients most in need of care.”
CCG Commissioning Lead

“By having jointly agreed guidelines and processes for what are complex – and often confusing – arrangements, it will simplify the system for professionals, as well as patients and carers.”
Marilyn Ekers, Acting Chair of North Yorkshire and York Neurological Alliance

Company Details

 Latest Content from  Wilmington Healthcare 

Considering a portfolio review?

Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...

UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW

Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...

MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE

With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...

ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS

With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...

HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW

Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...

ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE

With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.

Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed

Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...

EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES

As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...

UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS

Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...